ArticleFrontiers in pharmacology2019
The Coincidence Between Increasing Age, Immunosuppression, and the Incidence of Patients With Glioblastoma.
Open access · goldAbstract read
In one paragraph
Article in Frontiers in pharmacology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 75 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
75citing papers in PubMed, 1 pooled it
11.0field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
75 citing papers in PubMed, 1 synthesis or guideline pooled it, 127 citations in OpenAlex.
- Glioblastoma immunotherapy in the context of the aging immune system: a systematic review and meta-analysis.Journal of neuro-oncology · 2026Pooled it
- Chemokine-chemokine receptor axis: Emerging immunotherapeutic paradigms for solid tumor microenvironment reprogramming.Chinese medical journal · 2026Review
- Targeting ABC transporters in glioma: farnesiferols as potent agents against chemotherapy resistance.Neurogenetics · 2026Article
- Towards a personalized perspective on gliomas: an epigenetic-immuno-inflammatory aging framework.Frontiers in immunology · 2026Review
- Current strategies and novel immunotherapeutic approaches for overcoming immune resistance in glioblastoma.Discover oncology · 2025Review
- The glioma microenvironment and its impact on antitumor immunity.Neuro-oncology advances · 2025Review
- Association between autologous formalin-fixed tumor vaccine (AFTV) therapy, molecular pathological markers, and survival outcomes in glioblastoma.Brain tumor pathology · 2025Article
- Cell death in glioblastoma and the central nervous system.Cellular oncology (Dordrecht, Netherlands) · 2025Review
- Epidemiology and Outcome of Primary Central Nervous System Tumors Treated at King Hussein Cancer Center.Cancers · 2025Article
- Immunosenescence and age-related immune cells: causes of age-related diseases.Archives of pharmacal research · 2025Review
- Is modulation of immune checkpoints on glioblastoma-infiltrating myeloid cells a viable therapeutic strategy?Neuro-oncology · 2025Review
- Immune intrinsic escape signature stratifies prognosis, characterizes the tumor immune microenvironment, and identifies tumorigenic PPP1R8 in glioblastoma multiforme patients.Frontiers in immunology · 2025Article
- Fluorescent Particles Based on Aggregation-Induced Emission for Optical Diagnostics of the Central Nervous System.Research (Washington, D.C.) · 2025Review
- Review
- Epidemiology of malignant brain tumors in Genova, Italy. 1993-2017.Scientific reports · 2024Article
- Astrocytes and the tumor microenvironment inflammatory state dictate the killing of glioblastoma cells by Smac mimetic compounds.Cell death & disease · 2024Article
- The impact of the senescent microenvironment on tumorigenesis: Insights for cancer therapy.Aging cell · 2024Review
- The immunological landscape of peripheral blood in glioblastoma patients and immunological consequences of age and dexamethasone treatment.Frontiers in immunology · 2024Article
- 'Slicing' glioblastoma drivers with the Swiss cheese model.Trends in cancer · 2024Review
- Aging-related biomarker discovery in the era of immune checkpoint inhibitors for cancer patients.Frontiers in immunology · 2024Review
15 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 2 institutions in 1 country.
Erik LadomerskyDepartment of Neurological Surgery, Northwestern University Feinberg School of Medicine, Chicago, IL, United States.
Denise M ScholtensDepartment of Neurological Surgery, Northwestern University Feinberg School of Medicine, Chicago, IL, United States.
Masha KocherginskyDepartment of Preventive Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL, United States.
Elizabeth A HiblerDepartment of Preventive Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL, United States.
Elizabeth T BartomDepartment of Biochemistry and Molecular Genetics, Northwestern University Feinberg School of Medicine, Chicago, IL, United States.
Sebastian Otto-MeyerDepartment of Neurological Surgery, Northwestern University Feinberg School of Medicine, Chicago, IL, United States.
Lijie ZhaiDepartment of Neurological Surgery, Northwestern University Feinberg School of Medicine, Chicago, IL, United States.
Kristen L LauingDepartment of Neurological Surgery, Northwestern University Feinberg School of Medicine, Chicago, IL, United States.
Jaehyuk ChoiDepartment of Biochemistry and Molecular Genetics, Northwestern University Feinberg School of Medicine, Chicago, IL, United States.
Jeffrey A SosmanDepartment of Medicine-Hematology and Oncology, Northwestern University Feinberg School of Medicine, Chicago, IL, United States.
Jennifer D WuDepartment of Urology, Northwestern University Feinberg School of Medicine, Chicago, IL, United States.
Bin ZhangDepartment of Medicine-Hematology and Oncology, Northwestern University Feinberg School of Medicine, Chicago, IL, United States.
Rimas V LukasRobert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, Chicago, IL, United States.
Derek A WainwrightDepartment of Neurological Surgery, Northwestern University Feinberg School of Medicine, Chicago, IL, United States.
Northwestern University · USNeurological Surgery · US
Funding
Northwestern University Clinical and Translational Science Institute (NUCATS)UL1TR001422 · NCATS · NORTHWESTERN UNIVERSITY AT CHICAGO · PI D'AQUILA, RICHARD · 2015 to 2023
$56.8MSTINGing GBM: A First-in- Man Clinical Trial in Surgical Resectable Recurrent GBMP50CA221747 · NCI · NORTHWESTERN UNIVERSITY AT CHICAGO · PI Catalina Lee Chang · 2018 to 2026
$21.4MTRAINING PROGRAM IN SIGNAL TRANSDUCTION AND CANCERT32CA070085 · NCI · NORTHWESTERN UNIVERSITY AT CHICAGO · PI LEONIDAS C. PLATANIAS · 1997 to 2026
$5.7MIDO1 and Immunotolerance in GlioblastomaR01NS097851 · NINDS · NORTHWESTERN UNIVERSITY AT CHICAGO · PI SCHILTZ, GARY E, WAINWRIGHT, DEREK ALAN · 2016 to 2025
$4.6MBioinformatics Analysis of Next Generation Sequencing Data from Cancer CellsR50CA221848 · NCI · NORTHWESTERN UNIVERSITY AT CHICAGO · PI Elizabeth Thomas Bartom · 2017 to 2026
$1.8MTarget MIC shedding to revive anti-tumor immunityR01CA204021 · NCI · NORTHWESTERN UNIVERSITY AT CHICAGO · PI WU, JENNIFER D · 2016 to 2022
$1.8MNKG2D superagonist co-stimulation to enhance adaptive immunotherapy of cancerR01CA208246 · NCI · NORTHWESTERN UNIVERSITY AT CHICAGO · PI WU, JENNIFER D · 2016 to 2020
$1.8MTargeting MIC shedding to revive host NKG2D-mediated immune response in prostateR01CA149405 · NCI · UNIVERSITY OF WASHINGTON · PI WU, JENNIFER D · 2010 to 2014
$1.5MThe interaction of IDO and Tregs Leads to Immunosuppression in GliomaR00NS082381 · NINDS · NORTHWESTERN UNIVERSITY AT CHICAGO · PI WAINWRIGHT, DEREK ALAN · 2014 to 2016
$735kThe interaction of IDO and Tregs Leads to Immunosuppression in GliomaK99NS082381 · NINDS · UNIVERSITY OF CHICAGO · PI WAINWRIGHT, DEREK ALAN · 2013 to 2014
$173kThe role of IDO and Th17 in an experimental mouse model of gliomaF32NS073366 · NINDS · UNIVERSITY OF CHICAGO · PI WAINWRIGHT, DEREK ALAN · 2011 to 2012
$86kNCATS NIH HHS UL1 TR001422NCI NIH HHS P50 CA221747NCI NIH HHS R01 CA204021NCI NIH HHS R01 CA208246NCI NIH HHS R50 CA221848NCI NIH HHS T32 CA070085NINDS NIH HHS F32 NS073366NINDS NIH HHS K99 NS082381NINDS NIH HHS R00 NS082381NINDS NIH HHS R01 NS097851
Abstract
PubMed holds no abstract for this paper.
Indexed as
agingbiomarkerIDHIDOimmunosuppressionimmunotherapyPD-L1Treg
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.